LIFE HEALTHCARE GROUP HOLDINGS LTD

LIFE HEALTHCARE GROUP HOLDINGS LTD Organogram

Life Healthcare Group Holdings Ltd is an investment holding company and through its subsidiaries, joint ventures and associate companies operates as a private hospital operator in South Africa and primarily serves the market for privately insured individuals. The group provides mainly acute care and high technology private hospital services.\r\n\r\nSouthern Africa business activities are organised into two divisions, namely the hospital division and healthcare services division. International operations are located in Europe & UK as Alliance Medical (ALM) and Life Molecular Imaging (LMI).\r\n\r\nThe group includes the following operations and assets:\r\n\r\nSouthern Africa\r\n\r\n• Acute hospitals: Multi-disciplinary acute healthcare facilities with an array of high-quality services including emergency units, intensive care treatment, day surgical centres, and \r\non-site pharmacies.\r\n- 48 acute hospitals\r\n- 8,308 registered beds\r\n- 297 surgical theatres\r\n- 16 cathlabs\r\n- 2,011,564 PPDs\r\n- 20.9 million theatre minutes\r\n- 20,237 cathlab cases\r\n- 68.7% occupancy \r\n- 85.4% patient satisfaction score\r\n- 97.3% care bundle compliance \r\n\r\n• Acute rehabilitation: Physical rehabilitation facilities cater to patients with brain injuries, offering acute physical and cognitive rehabilitation.\r\n- 7 facilities\r\n- 287 beds\r\n- 2,528 admissions\r\n- 69 650 PPDs\r\n- 70.0% Occupancy\r\n\r\n• Mental health: Multi-disciplinary mental healthcare service offerings designed for transitory care in a therapeutic and tranquil environment. Facilities house voluntary, assisted, and involuntary mental \r\nhealthcare users.\r\n- 9 facilities\r\n- 607 beds\r\n- 15,187 admissions\r\n- 159,838 PPDs\r\n- 72.5% Occupancy\r\n\r\n• Renal dialysis: Renal facilities for patients with acute or chronic renal disease who need outpatient-based chronic dialysis, inpatient-based acute renal dialysis, or home\r\nbased peritoneal dialysis.\r\n- 71 facilities\r\n- 1,012 renal stations\r\n- 369,106 treatment\r\n\r\n• Oncology: oncology centres offer a holistic care model with technologically advanced diagnostic and interventional services supporting comprehensive cancer management.\r\n- 5 Facilities\r\n- 32,262 Treatments\r\n\r\n• Diagnostics: imaging and nuclear medicine: Non-clinical diagnostic imaging services at Life Eugene Marias Hospital and at hospitals in the Eastern Cape and Botswana.\r\n- 10 imaging facilities\r\n- 3 nuclear medicine facilities, including PET-CT and SPECT (2023: 3)\r\n- 41,284 MRI and CT scans \r\n- 196,689 X-ray and other scans\r\n- 796 SPECT and 2 402 PET-CT scans\r\n\r\n• Life Nkanyisa: Offers specialised care for vulnerable patients in society, partnering with South Africa’s provincial health and social development departments to provide \r\ncomprehensive, long-term services for patients requiring frail care, chronic mental healthcare, and substance abuse support.\r\n- 7 facilities\r\n- 2,308 beds\r\n- 1,052,388 PPDs \r\n\r\n• Life Health Solutions: Offers an integrated health risk-management service providing wellness programmes, and occupational and primary healthcare to corporate and institutional clients. Also provides contracted on-site occupational, primary and emergency healthcare services to large private and public employees.\r\n- 253 Occupational Health Clinics\r\n- 460,950 Enrolled employees\r\n\r\nInternational (Europe and the United Kingdom): \r\n\r\nThe Alliance Medical Group (AMG) disposal was concluded on 31 January 2024. The Company received a net R10.2 billion in cash proceeds, and a special dividend of R8.8 billion was paid to shareholders on 8 April 2024.\r\n\r\nLife Molecular Imaging (LMI) - Fully integrated research and development pharmaceutical company dedicated to developing and commercialising innovative molecular imaging agents for use globally in PET-CT diagnostics.\r\n• NeuraCeq® - US FDA, EMA and UK MHRA approved diagnostic radioisotope for determining whether amyloid plaques are present in the brains of patients with suspected Alzheimer’s Disease.\r\n• 36 Manufacturing sites active and contracted third-party manufacturing sites around the world